Medidata Solutions

Medidata Solutions

Cloud-based software for clinical trials

Overview

Medidata Solutions provides cloud-based software for clinical trials in the life sciences field. It serves pharmaceutical, biotech, and medical device companies, as well as academic institutions and contract research organizations, with tools that cover study design, data capture, and analysis. Core products include Rave EDC, eCOA, ePRO, and Rave Coder, all delivered via a subscription-based licensing model to collect, manage, and analyze trial data in a unified cloud platform. The goal is to help clients bring new treatments to market faster and at lower costs by using end-to-end data-driven insights and responsible business practices.

About Medidata Solutions

Simplify's Rating
Why Medidata Solutions is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

Healthcare

Company Size

1,001-5,000

Company Stage

Acquired

Total Funding

$5.8B

Headquarters

New York City, New York

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Menarini's 14-year partnership expands with AI for in-house oncology studies.
  • Bristol Myers Squibb extends multi-year deal adding AI analytics and Clinical Data Studio.
  • Cognizant alliance accelerates R&D via dedicated support for 2,300 customers.

What critics are saying

  • Oracle's March 2025 Certara acquisition undercuts Rave EDC pricing, capturing 50-70% share in 12-24 months.
  • Veeva Vault poaches biotech clients with 30% faster decentralized trials in 6-12 months.
  • Epic Cosmos' April 2026 expansion obsoletes Patient Cloud for 70% US sites in 6-12 months.

What makes Medidata Solutions unique

  • Medidata AI Study Build slashes oncology trial setup from months to weeks using 38,000 trials' data.
  • IXICO partnership integrates neuroimaging analytics across Medidata's 38,000 global trials.
  • UK NIHR iCT integration into Grants Manager boosts budgeting precision by 80%.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$5.8B

Above

Industry Average

Funded Over

4 Rounds

Notable Investors:
Acquisition funding comparison data is currently unavailable. We're working to provide this information soon!
Acquisition Funding Comparison
Coming Soon

Benefits

Unlimited Paid Time Off

Health & Wellness

Professional Development

Work/Life Balance

Maternity & Paternity Leave

Company News

Yahoo Finance
Mar 29th, 2026
IXICO partners with Medidata to scale neuroimaging analytics across 38,000 clinical trials

IXICO has announced a strategic collaboration with Medidata, combining IXICO's neuroimaging analytics with Medidata's global clinical trial platform to create a seamless solution for biopharma trials. CEO Bram Goorden described the partnership as a significant step into the "tech bio" space. Medidata serves 18 of the top 25 pharmaceutical companies and supports around 38,000 trials across 140 geographies. The collaboration gives IXICO access to larger, more complex trials and is expected to generate recurring revenue streams. The deal follows recent contract wins, including a £1.5 million Phase 2 trial extension, and the appointment of Tanya Voloshen as Chief Commercial Officer. Goorden said the partnership marks a new chapter for the imaging contract research organisation, positioning it to scale whilst maintaining its core business focus.

The Associated Press
Mar 9th, 2026
Medidata expands Menarini partnership with AI Study Build to accelerate oncology trials

Medidata, a Dassault Systèmes brand, has expanded its partnership with The Menarini Group and its subsidiary Stemline Therapeutics to accelerate oncology clinical trials using AI Study Build technology. The technology leverages data from over 38,000 trials to automate configurations, reducing the time between protocol finalisation and trial startup from months to weeks. Stemline recently launched its first oncology study entirely in-house using Medidata's platform. The AI-powered system enables rapid study startups, internal agility for building future trials independently, and faster delivery of high-quality data for cancer research. The expansion builds on a 14-year relationship between Menarini and Medidata. Whilst Menarini has long used Medidata's platform including Rave EDC and eCOA, the adoption of AI Study Build marks a significant advancement in streamlining clinical trial workflows.

The Associated Press
Feb 11th, 2026
Medidata's AI powers 500+ clinical studies with new generative AI tool slashing trial setup times

Medidata, a Dassault Systèmes brand providing clinical trial solutions, has deployed AI technology across over 500 clinical studies in the past decade, with more than 120 AI-supported studies launching in 2025 alone. The company has introduced Medidata AI Study Build, which uses generative AI to configure trial systems by leveraging study protocols, significantly reducing time from protocol to start-up. The technology draws on data from more than 38,000 trials to accelerate clinical development. Medidata is expanding Dot, its AI orchestrator that connects domain-specific AI capabilities across its platform. The company's unified platform aims to streamline complex database builds and accelerate market access for new therapies. Medidata serves approximately 2,300 customers with over 1 million registered users.

PharmiWeb.com
Feb 12th, 2025
Medidata Becomes First Life Sciences Company To Integrate Uk Mandated Health Costing Data Into Its Financial Management Portfolio

Incorporating the UK integrated Costing Tool (iCT) pricing into Medidata Grants Manager is expected to amplify UK budget precision by up to 80%London – 11 Feb., 2025 – Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has integrated data from the UK interactive Costing Tool (iCT ) , hosted by the National Institute for Health and Care Research (NIHR), into Medidata Grants Manager, creating a first-of-its-kind offering in the life sciences space. This will consolidate study budgeting with consistent costs, coding, and processes.“The ability for clinical trial teams to efficiently develop grant budgets and administer site negotiations is a crucial function of a trial,” said Meghan Harrington, vice president, clinical financial management, Medidata. “Incorporating the UK iCT into Grants Manager streamlines the study start up process and improves budget precision by up to 80%.”The UK approach for commercial study costing and contracting relies on a standardized budget template with specific codes and costs to ensure efficient budget preparation. The manual transfer of data from the UK iCT system into budgeting applications creates inefficiencies, including delays and duplication of efforts that increase the risk of errors. Integrating UK iCT data directly into Grants Manager overcomes these challenges by eliminating the need for manual data entry, significantly reducing preparation time and supporting data consistency across platforms.“Our overarching mission as an organization is to advance the nation’s health through groundbreaking research, and with Medidata’s support, we are proudly positioning the UK as a global leader in this endeavor,” said Laura Bousfield, national research delivery director, NIHR. “This Medidata solution empowers us to improve UK budget accuracy, creating a process that is more systematic and reliable

HIT Consultant
Feb 11th, 2025
Medidata Integrates Uk Costing Data Into Grants Manager, Streamlining Clinical Trial Budgeting

What You Should Know:– Medidata, a Dassault Systèmes brand and a leading provider of clinical trial solutions, today announced the integration of data from the UK interactive Costing Tool (iCT) into its Grants Manager platform.– The collaboration with the National Institute for Health and Care Research (NIHR) provides life sciences organizations with a streamlined and standardized approach to clinical trial budgeting, enhancing efficiency and transparency in research funding.Partnership with NIHR Enhances Efficiency and Transparency in Research FundingThe iCT, hosted by the NIHR, provides a centralized resource for costing clinical research in the UK. By integrating this data into Grants Manager, Medidata enables researchers and sponsors to:Access consistent cost data: Utilize standardized cost information for various aspects of clinical trials, ensuring accuracy and consistency in budget development.Utilize standardized cost information for various aspects of clinical trials, ensuring accuracy and consistency in budget development. Simplify budget creation: Automate the process of generating budgets, reducing manual effort and improving efficiency.Automate the process of generating budgets, reducing manual effort and improving efficiency. Enhance transparency: Promote transparency in research funding by providing clear and consistent cost information to all stakeholders.Collaboration with NIHRMedidata has worked closely with the NIHR to ensure the seamless integration of iCT data into Grants Manager. The company’s active participation in the National Contract Value Review Advisory Board and UK Commercial Costing Reference Group further demonstrates its commitment to advancing best practices in clinical trial budgeting.“The ability for clinical trial teams to efficiently develop grant budgets and administer site negotiations is a crucial function of a trial,” said Meghan Harrington, vice president, clinical financial management, Medidata. “Incorporating the UK iCT into Grants Manager streamlines the study start up process and improves budget precision by up to 80%.”The UK approach for commercial study costing and contracting relies on a standardized budget template with specific codes and costs to ensure efficient budget preparation

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Medidata Solutions right now.

Find jobs on Simplify and start your career today

We update Medidata Solutions's jobs every few hours, so check again soon! Browse all jobs →